{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:38:26Z","timestamp":1794476306987,"version":"4.9.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:p>\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Background:<\/jats:italic>\n                    <\/jats:bold>\n                    Cefazolin is a common antibiotic for methicillin-susceptible\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (MSSA) bacteremia. Type A or C \u03b2-lactamase-producing MSSA frequently shows the cefazolin inoculum effect (CIE). However, the clinical implication of the CIE for MSSA bacteremia is obscure.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Methods:<\/jats:italic>\n                    <\/jats:bold>\n                    MSSA bacteremic patients treated with cefazolin were included in a retrospective cohort study. The\n                    <jats:italic toggle=\"yes\">blaZ<\/jats:italic>\n                    gene of the isolates was sequenced to identify the type of \u03b2-lactamase. The patients whose isolates showed a \u22654-fold increase in cefazolin, the minimal inhibitory concentration (MIC) at the high inoculum (\u223c5\u00d710\n                    <jats:sup>7<\/jats:sup>\n                    CFU\/ml), were assigned to the CIE-positive group and the remainder to the CIE-negative group. Treatment failure was assessed at 12 weeks after cefazolin was initiated.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Results:<\/jats:italic>\n                    <\/jats:bold>\n                    A total of 113 MSSA bacteremic patients were included. Among the 113 isolates, 57.5% showed the CIE and 77.9% carried the\n                    <jats:italic toggle=\"yes\">blaZ<\/jats:italic>\n                    gene; type A \u03b2-lactamase was 15.0% and type C was 40.7%. Persistent bacteremia was more common in the CIE-positive group (9% vs. 0%,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.04). Treatment failure rates were higher in the CIE-positive group with high bacterial burden infection, but the difference was not significant (48% vs. 25%,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.13). There was no significant difference of failure between groups with high-inoculum MIC \u226516 and \u22641\u2009\u03bcg\/ml (13% vs. 5%,\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    =0.31). In the multivariable analysis, underlying cardiovascular diseases, pneumonia, osteoarticular infections, and endocarditis were significant risk factors for treatment failure and the CIE was not significantly associated with treatment failure.\n                    <jats:bold>\n                      <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                    <\/jats:bold>\n                    The CIE might be associated with persistent bacteremia if cefazolin is used for MSSA bacteremia with a high burden of infections. However, the sites of infections are more important factors for the clinical outcome than the CIE.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2013.0229","type":"journal-article","created":{"date-parts":[[2014,7,7]],"date-time":"2014-07-07T09:58:26Z","timestamp":1404727106000},"page":"568-574","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":59,"title":["Clinical Implications of Cefazolin Inoculum Effect and \u03b2-Lactamase Type on Methicillin-Susceptible\n                    <i>Staphylococcus aureus<\/i>\n                    Bacteremia"],"prefix":"10.1177","volume":"20","author":[{"given":"Shinwon","family":"Lee","sequence":"first","affiliation":[{"name":"Pusan National University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Tae","family":"Kwon","sequence":"additional","affiliation":[{"name":"Daegu Fatima Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-In","family":"Kim","sequence":"additional","affiliation":[{"name":"Kyungpook National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ha","family":"Chang","sequence":"additional","affiliation":[{"name":"Kyungpook National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Myung","family":"Lee","sequence":"additional","affiliation":[{"name":"Kyungpook National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pyoeng Gyun","family":"Choe","sequence":"additional","affiliation":[{"name":"Seoul National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Beom","family":"Park","sequence":"additional","affiliation":[{"name":"Seoul National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam Joong","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myoung-Don","family":"Oh","sequence":"additional","affiliation":[{"name":"Seoul National University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Song","sequence":"additional","affiliation":[{"name":"Daegu Fatima Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Kyungpook National University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,12]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3201\/eid1706.101037","article-title":"High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia","volume":"17","author":"Aguado J.M.","year":"2011","unstructured":"Aguado J.M., , San-Juan R., , Lalueza A., , Sanz F., , Rodriguez-Otero J., , Gomez-Gonzalez C., , and Chaves F.. 2011. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteremia. Emerg. Infect. Dis., 17:1099\u20131102.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000153812.64956.EF"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1977.03270330059022"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/infdis\/147.6.1078","article-title":"Staphylococcal beta-lactamase and efficacy of beta-lactam antibiotics: in vitro and in vivo evaluation","volume":"147","author":"Chapman S.W.","year":"1983","unstructured":"Chapman S.W., , and Steigbigel R.T.. 1983. Staphylococcal beta-lactamase and efficacy of beta-lactam antibiotics: in vitro and in vivo evaluation. J. Infect. Dis., 147:1078\u20131089.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2334-8-14","article-title":"Epidemiology and outcomes of community-onset methicillin-susceptible Staphylococcus aureus bacteraemia in a university hospital in Singapore","volume":"8","author":"Chia J.W.","year":"2008","unstructured":"Chia J.W., , Hsu L.Y., , Chai L.Y., , and Tambyah P.A.. 2008. Epidemiology and outcomes of community-onset methicillin-susceptible Staphylococcus aureus bacteraemia in a university hospital in Singapore. BMC Infect. Dis., 8:14.","journal-title":"BMC Infect. Dis."},{"key":"e_1_3_3_7_2","unstructured":"Clinical and Laboratory Standards Institute. 2008. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90361-Z"},{"key":"e_1_3_3_9_2","doi-asserted-by":"crossref","unstructured":"Fowler V.G.Jr. Scheld W. Bayer M.. 2010. Endocarditis and Intravascular infections. In Mandell G.L. (ed.) Principles and Practice of Infectious Diseases. 7th ed. Churchill Livingstone Philadelphia pp. 1067\u20131112.","DOI":"10.1016\/B978-0-443-06839-3.00077-1"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/infdis\/141.3.331","article-title":"Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus","volume":"141","author":"Goldman P.L.","year":"1980","unstructured":"Goldman P.L., , and Petersdorf R.G.. 1980. Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus. J. Infect. Dis., 141:331\u2013337.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1128\/AAC.48.12.4618-4623.2004","article-title":"Amoxicillin-clavulanate therapy increases childhood nasal colonization by methicillin-susceptible Staphylococcus aureus strains producing high levels of penicillinase","volume":"48","author":"Guillemot D.","year":"2004","unstructured":"Guillemot D., , Bonacorsi S., , Blanchard J.S., , Weber P., , Simon S., , Guesnon B., , Bingen E., , and Carbon C.. 2004. Amoxicillin-clavulanate therapy increases childhood nasal colonization by methicillin-susceptible Staphylococcus aureus strains producing high levels of penicillinase. Antimicrob. Agents Chemother., 48:4618\u20134623.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir270"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/1469-0691.12168","article-title":"Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia","volume":"19","author":"Holmes N.E.","year":"2013","unstructured":"Holmes N.E., , Turnidge J.D., , Munckhof W.J., , Robinson J.O., , Korman T.M., , O'Sullivan M.V., , Anderson T.L., , Roberts S.A., , Warren S.J., , Gao W., et al. 2013. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia. Clin. Microbiol. Infect., 19:1163\u20131168.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1128\/AAC.34.3.420","article-title":"Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants","volume":"34","author":"Kernodle D.S.","year":"1990","unstructured":"Kernodle D.S., , McGraw P.A., , Stratton C.W., , and Kaiser A.B.. 1990. Use of extracts versus whole-cell bacterial suspensions in the identification of Staphylococcus aureus beta-lactamase variants. Antimicrob. Agents Chemother., 34:420\u2013425.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/159.1.103","article-title":"Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles","volume":"159","author":"Kernodle D.S.","year":"1989","unstructured":"Kernodle D.S., , Stratton C.W., , McMurray L.W., , Chipley J.R., , and McGraw P.A.. 1989. Differentiation of beta-lactamase variants of Staphylococcus aureus by substrate hydrolysis profiles. J. Infect. Dis., 159:103\u2013108.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-07"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/589717"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00485-11"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1128\/AAC.00052-12","article-title":"Prevalence of blaZ gene types and the inoculum effect with cefazolin among bloodstream isolates of methicillin-susceptible Staphylococcus aureus","volume":"56","author":"Livorsi D.J.","year":"2012","unstructured":"Livorsi D.J., , Crispell E., , Satola S.W., , Burd E.M., , Jerris R., , Wang Y.F., , and Farley M.M.. 2012. Prevalence of blaZ gene types and the inoculum effect with cefazolin among bloodstream isolates of methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother., 56:4474\u20134477.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"0137","DOI":"10.1056\/NEJM196505202722002","article-title":"Treatment of pyelonephritis: bacterial, drug and host factors in success or failure among 252 patients","volume":"272","author":"McCabe W.R.","year":"1965","unstructured":"McCabe W.R., , and Jackson G.G.. 1965. Treatment of pyelonephritis: bacterial, drug and host factors in success or failure among 252 patients. N. Engl. J. Med., 272:0137\u20130144.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/317421"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1128\/AAC.00856-13","article-title":"In vivo effect of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible Staphylococcus aureus strain showing an inoculum effect against cefazolin","volume":"57","author":"Nannini E.C.","year":"2013","unstructured":"Nannini E.C., , Singh K.V., , Arias C.A., , and Murray B.E.. 2013. In vivo effect of cefazolin, daptomycin, and nafcillin in experimental endocarditis with a methicillin-susceptible Staphylococcus aureus strain showing an inoculum effect against cefazolin. Antimicrob. Agents Chemother., 57:4276\u20134281.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1086\/379021","article-title":"Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue","volume":"37","author":"Nannini E.C.","year":"2003","unstructured":"Nannini E.C., , Singh K.V., , and Murray B.E.. 2003. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin. Infect. Dis., 37:1194\u20131198.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00317-09"},{"key":"e_1_3_3_25_2","first-page":"207","article-title":"Staphylococcal biofilms","volume":"322","author":"Otto M","year":"2008","unstructured":"Otto M. 2008. Staphylococcal biofilms. Curr. Top. Microbiol. Immunol., 322:207\u2013228.","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1093\/infdis\/128.Supplement_2.S386","article-title":"Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis","volume":"128","author":"Quinn E.L.","year":"1973","unstructured":"Quinn E.L., , Pohlod D., , Madhavan T., , Burch K., , Fisher E., , and Cox F.. 1973. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J. Infect. Dis., 128 Suppl:S386\u2013S389.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0076-6879(75)43082-8","article-title":"Immunological techniques for studying beta-lactamases","volume":"43","author":"Richmond M.H.","year":"1975","unstructured":"Richmond M.H. 1975. Immunological techniques for studying beta-lactamases. Methods Enzymol., 43:86\u2013100.","journal-title":"Methods Enzymol."},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/jac\/dkt254","article-title":"Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals","volume":"68","author":"Rincon S.","year":"2013","unstructured":"Rincon S., , Reyes J., , Carvajal L.P., , Rojas N., , Cortes F., , Panesso D., , Guzman M., , Zurita J., , Adachi J.A., , Murray B.E., et al. 2013. Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals. J. Antimicrob. Chemother., 68:2773\u20132778.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_29_2","first-page":"175","article-title":"Penicillinase production in Staphylococcus aureus strains of clinical importance","volume":"33","author":"Rosdahl V.T.","year":"1986","unstructured":"Rosdahl V.T. 1986. Penicillinase production in Staphylococcus aureus strains of clinical importance. Dan. Med. Bull., 33:175\u2013184.","journal-title":"Dan. Med. Bull."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki385"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05022-11"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/AAC.42.12.3163","article-title":"Characterization of a chromosomal gene encoding type B beta-lactamase in phage group II isolates of Staphylococcus aureus","volume":"42","author":"Voladri R.K.","year":"1998","unstructured":"Voladri R.K., , and Kernodle D.S.. 1998. Characterization of a chromosomal gene encoding type B beta-lactamase in phage group II isolates of Staphylococcus aureus. Antimicrob. Agents Chemother., 42:3163\u20133168.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1128\/jb.178.24.7248-7253.1996","article-title":"Structure-function relationships among wild-type variants of Staphylococcus aureus beta-lactamase: importance of amino acids 128 and 216","volume":"178","author":"Voladri R.K.","year":"1996","unstructured":"Voladri R.K., , Tummuru M.K., , and Kernodle D.S.. 1996. Structure-function relationships among wild-type variants of Staphylococcus aureus beta-lactamase: importance of amino acids 128 and 216. J. Bacteriol., 178:7248\u20137253.","journal-title":"J. Bacteriol."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.2.440"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2013.0229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2013.0229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2013.0229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:28:20Z","timestamp":1777667300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2013.0229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1089\/mdr.2013.0229"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2013.0229","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}